IL323835A - Bifunctional small molecules to target the selective degradation of circulating proteins - Google Patents

Bifunctional small molecules to target the selective degradation of circulating proteins

Info

Publication number
IL323835A
IL323835A IL323835A IL32383525A IL323835A IL 323835 A IL323835 A IL 323835A IL 323835 A IL323835 A IL 323835A IL 32383525 A IL32383525 A IL 32383525A IL 323835 A IL323835 A IL 323835A
Authority
IL
Israel
Prior art keywords
linker
targeting ligand
extracellular protein
group
pct
Prior art date
Application number
IL323835A
Other languages
English (en)
Hebrew (he)
Inventor
Gene M Dubowchik
Wieslaw Kazmierski
Original Assignee
Biohaven Therapeutics Ltd
Gene M Dubowchik
Wieslaw Kazmierski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Gene M Dubowchik, Wieslaw Kazmierski filed Critical Biohaven Therapeutics Ltd
Publication of IL323835A publication Critical patent/IL323835A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL323835A 2023-04-28 2025-10-08 Bifunctional small molecules to target the selective degradation of circulating proteins IL323835A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363498852P 2023-04-28 2023-04-28
US202363517984P 2023-08-07 2023-08-07
PCT/US2024/026709 WO2024227119A2 (en) 2023-04-28 2024-04-28 Bifunctional small molecules to target the selective degradation of circulating proteins

Publications (1)

Publication Number Publication Date
IL323835A true IL323835A (en) 2025-12-01

Family

ID=93257447

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323835A IL323835A (en) 2023-04-28 2025-10-08 Bifunctional small molecules to target the selective degradation of circulating proteins

Country Status (7)

Country Link
EP (1) EP4704832A2 (de)
KR (1) KR20250172727A (de)
CN (1) CN121127237A (de)
AU (1) AU2024264049A1 (de)
IL (1) IL323835A (de)
MX (1) MX2025012651A (de)
WO (1) WO2024227119A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025219911A1 (en) * 2024-04-16 2025-10-23 Biohaven Therapeutics Ltd. Treatment of diseases with monoclonal antibody drugs and molecular degraders
WO2025248469A1 (en) 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES
WO2026028158A1 (en) 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101525298B1 (ko) * 2012-01-18 2015-06-03 고려대학교 산학협력단 3,6-안하이드로-l-갈락토오스의 제조방법 및 이의 용도
EP3658170A4 (de) * 2017-07-26 2021-08-25 Kleo Pharmaceuticals, Inc. Universelle abt-verbindungen und ihre verwendungen
EP4334360A2 (de) * 2021-05-03 2024-03-13 Avilar Therapeutics, Inc. Wirksame aspr-bindende verbindungen zum abbau von immunglobulinen und anderen proteinen

Also Published As

Publication number Publication date
AU2024264049A1 (en) 2025-11-27
MX2025012651A (es) 2025-11-03
EP4704832A2 (de) 2026-03-11
KR20250172727A (ko) 2025-12-09
CN121127237A (zh) 2025-12-12
WO2024227119A2 (en) 2024-10-31
WO2024227119A3 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
WO2019199621A4 (en) Bi-functional molecules to degrade circulating proteins
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
JP2011515478A5 (de)
JP2023175957A5 (de)
JP2021521192A5 (de)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
AU2023251416A1 (en) Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP2022549169A5 (de)
WO2019199634A4 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
JP2014516964A5 (de)
WO2016197114A1 (en) Tank-binding kinase-1 protacs and associated methods of use
RU2018105094A (ru) Модуляторы протеолиза на основе аланина и связанные с ними способы применения
JP2025509730A5 (de)
JP2019503674A5 (de)
RU2020139890A (ru) Имидные модуляторы протеолиза и способы их применения
JP2016519091A5 (de)
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
AU2017341723A1 (en) Compounds and methods for the targeted degradation of androgen receptor
RU2014133019A (ru) Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
JP2011519868A5 (de)
RU2017145267A (ru) Модуляторы протеолиза на основе имидов и связанные с ними способы применения
CA3153853A1 (en) Targeted bifunctional degraders
CA3118041A1 (en) Novel cytostatic conjugates with integrin ligands
CA3107377A1 (en) Boronic acid derivatives
KR20200119246A (ko) Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법